Skip to main content

The independent medical news service

20-01-2023 | Oncology | News | Article

IL-7 genetic variant linked to ICI toxicity

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

20-07-2022 | Oncology | News | Article

Pembrolizumab therapy linked to ‘distinctive’ facial brainstem sensory syndrome

A novel segmental facial brainstem sensory syndrome has been identified in three patients treated with pembrolizumab, thought to be caused by autoantibody binding to the surface of neurons.

26-05-2022 | Oncology | News | Article

Antibiotics tied to poor NSCLC, melanoma TKI outcomes

Antibiotic use is associated with poor survival outcomes in people receiving tyrosine kinase inhibitors for advanced non-small-cell lung cancer or melanoma, findings indicate.

Neurons_illustration (iStock-1224591033)

27-04-2022 | Oncology | News | Article

Neurologic AE risk lower with ICIs vs chemotherapy

The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.

IV drip

08-11-2021 | Oncology | News | Article

ICI monotherapy benefits cancer patients aged 80 and older

Age alone should not preclude the use of immune checkpoint inhibitors in people with cancer aged 80 years or more, say researchers who found promising efficacy and tolerability of single-agent therapy in this patient population.

26-10-2021 | Oncology | News | Article

ICIs linked to increased venous thromboembolism risk

A large single-center study has found an association between immune checkpoint inhibitor use and an increased incidence of venous thromboembolism in people with cancer.